Assessing Brexpiprazole for Schizophrenia and Depression
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders: a Naturalistic Non-interventional Prospective Follow-up Study
This study is testing how well brexpiprazole works and how easy it is to tolerate for adults with schizophrenia or depression who have just started taking the medication.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05962216 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the real-life efficacy and tolerability of brexpiprazole in adult patients diagnosed with psychotic disorders or major depressive disorder. Participants aged 18-65 who have been prescribed brexpiprazole for less than four weeks will be monitored over a six-month period. The study aims to gather data on the drug's performance in a naturalistic setting, focusing on its benefits and side effects. Minimal exclusion criteria are applied to reflect typical clinical practice.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 who have recently started treatment with brexpiprazole for psychosis or as an adjunct for major depressive disorder.
Not a fit: Patients under 18 years old or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and safety of brexpiprazole for treating schizophrenia and depression.
How similar studies have performed: Other studies have shown promise in evaluating the efficacy of second-generation antipsychotics like brexpiprazole, suggesting that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18- 65 years old at the time of enrollment * Able to read and communicate in English and/or Chinese * Able to give informed consent * Has been diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), or International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) to have either Psychotic Disorders (F10-F19.5, F20-23, F25, F32-F33) * is receiving brexpiprazole as treatment for less than 4 weeks at the time of recruitment Exclusion Criteria: * Age \<18 years old * Unable to read English or Chinese * Unable to give informed consent * Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Where this trial is running
Hong Kong
- Queen Mary Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Albert KK Chung, MBBS
- Email: Chungkka@hku.hk
- Phone: 2255 4486
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.